Benchmark lowered the firm’s price target on Constellium (CSTM) to $18 from $24 and keeps a Buy rating on the shares. Constellium beat Q1 expectations and reiterated guidance, which while similar to other reports this quarter, had a more positive impact on the shares given uncertainty around end-market exposure, the analyst tells investors. The firm has lowered its price target to reflect current uncertainty, the analyst noted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CSTM: